Fujisawa City, Japan — GemPharmatech, Ltd., a global provider of genetically engineered mouse models and services, is pleased to announce that they have entered into a distribution agreement with Fujifilm Wako Pure Chemical Corporation and Institute of Immunology Co., Ltd., that significantly improves Japanese researcher access to innovative mouse models and preclinical services.

The agreement establishes Fujifilm Wako and Institute of Immunology Co., Ltd., as distribution partners for GemPharmatech’s portfolio of over 25,000 mouse models including knockout, conditional knockout, humanized, immunodeficient and disease-specific models. In addition, Japanese researchers will have more streamlined access to GemPharmatech’s preclinical pharmacology services.

“This collaboration with Fujifilm Wako and the Institute of Immunology will make it easier and more convenient for Japanese researchers to access our preclinical services and comprehensive collection of models,” said Dr. Brandy Wilkinson, Chief Executive Officer of GemPharmatech. “By combining Fujifilm Wako Pure Chemical’s strong reputation Institute of Immunology’s technical expertise with our innovative resources, we are strengthening our ability to support biomedical discovery in Japan.”

Under the arrangement, Fujifilm Wako Pure Chemical will oversee sales distribution across Japan, while Institute of Immunology Co., Ltd., will provide operational and technical support, including training and customer communication.

“Institute of Immunology Co., Ltd., mission is to contribute to a healthier society by providing specialty bioresources that contribute to diagnostics and drug discovery. We contribute to drug development by providing rapid services that incorporate GemPharmatech's technology.” said Yukio Ito, President and CEO of Institute of Immunology Co., Ltd.

Japan’s pharmaceutical industry has a reputation for innovative drug research and development, and this partnership enables researchers access to GemPharmatech’s Knockout All Project library, genetically humanized strains, and next generation immunodeficient models coupled with localized distribution and support. Strategically, the agreement underscores GemPharmatech’s global expansion efforts to make advanced preclinical resources more accessible to the biomedical research community worldwide.

“For GemPharmatech, this is more than a distribution agreement. It is an important step in our strategy to build strong regional partnerships that bring our innovative models and services closer to the researchers who need them,” said Dr. Xiang Gao, Chairman and founder of GemPharmatech. “Expanding in Japan through trusted partners like Fujifilm Wako Pure Chemical and Institute of Immunology reflects our long-term vision of supporting scientific discovery globally by ensuring access, trust, and collaboration at the local level.”